sorafenib has been researched along with Minimal Disease, Residual in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Berg, T; Bethge, W; Böhm, A; Bornhäuser, M; Brandts, C; Brugger, M; Bug, G; Burchardt, A; Burchert, A; Crysandt, M; Ehninger, G; Eßeling, E; Finke, J; Fritz, LV; Götze, KS; Haferlach, T; Harnisch, S; Hoeffkes, HG; Kröger, N; Lang, F; Metzelder, SK; Michel, C; Neubauer, A; Röllig, C; Rospleszcz, S; Schade-Brittinger, C; Schleuning, M; Schmid, C; Serve, H; Stelljes, M; Strauch, K; Thiede, C; Wagner, EM; Wang, Y; Wäsch, R; Wittenberg, M; Wolf, D; Wollmer, E; Wolschke, C; Wündisch, T; Zeiser, R | 1 |
| Chen, Q; Huang, XF; Li, S; Tang, Z; Wang, W; Wu, L; Zhai, L; Zhou, J; Zhou, W | 1 |
| Chen, RX; Cui, JF; Dong, G; Dong, YY; Gao, DM; Li, JH; Ma, H; Ma, M; Ren, ZG; Yao, RR; Zhang, R; Zheng, QD | 1 |
| Gao, C; Gu, Z; Huang, W; Liu, Z; Wang, L; Wang, S; Yang, N | 1 |
| Adlard, K; Chang, B; Cooper, T; Estey, E; Garee, A; Gross, T; Gupta, S; Ho, PA; McGoldrick, S; Meshinchi, S; Neudorf, S; Pollard, JA; Sisler, I; Tarlock, K; Templeman, T; Thomson, B; Watt, T; Woolfrey, A | 1 |
| Cai, H; Kong, WT; Tang, Y; Wang, WP; Zhang, XL | 1 |
1 trial(s) available for sorafenib and Minimal Disease, Residual
| Article | Year |
|---|---|
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Double-Blind Method; Female; fms-Like Tyrosine Kinase 3; Germany; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mutation; Neoplasm, Residual; Protein Kinase Inhibitors; Recurrence; Sorafenib; Tandem Repeat Sequences; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2020 |
5 other study(ies) available for sorafenib and Minimal Disease, Residual
| Article | Year |
|---|---|
Sorafenib blocks the activation of the HIF-2α/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo.
Topics: Angiogenesis Inhibitors; Animals; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Proliferation; Chemotherapy, Adjuvant; Gene Expression Regulation, Neoplastic; Hep G2 Cells; High-Intensity Focused Ultrasound Ablation; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm, Residual; Protein Kinase Inhibitors; Receptor, EphA2; Signal Transduction; Sorafenib; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2021 |
Increased matrix stiffness promotes tumor progression of residual hepatocellular carcinoma after insufficient heat treatment.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Combined Modality Therapy; Disease Progression; Enzyme Activation; Extracellular Matrix; Extracellular Signal-Regulated MAP Kinases; Humans; Hyperthermia, Induced; Liver Neoplasms, Experimental; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm, Residual; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Vitamin K 1; Xenograft Model Antitumor Assays | 2017 |
Sorafenib as a Salvage Therapy in FLT3-ITD Negative Relapse/ Refractory Acute Myeloid Leukemia.
Topics: Adolescent; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Structure; Neoplasm, Residual; Protein Kinase Inhibitors; Salvage Therapy; Sorafenib; Structure-Activity Relationship | 2018 |
Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Tandem Repeat Sequences | 2015 |
Microwave coagulation/ablation in combination with sorafenib suppresses the overgrowth of residual tumor in VX2 liver tumor model.
Topics: Animals; Catheter Ablation; Cell Line, Tumor; Chemotherapy, Adjuvant; Contrast Media; Diffusion Magnetic Resonance Imaging; Immunohistochemistry; Liver; Liver Neoplasms, Experimental; Microwaves; Necrosis; Neoplasm, Residual; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rabbits; Sorafenib; Ultrasonography | 2016 |